Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

S 81694

Next Previous
Drug Profile

S 81694

Alternative Names: NMS P153; NMS-01940153E; NMS-153; S-81694

Latest Information Update: 08 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Nerviano Medical Sciences; Servier
  • Class Antineoplastics; Small molecules
  • Mechanism of Action TTK protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer; Liver cancer
  • Preclinical Acute myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • No development reported Solid tumours

Most Recent Events

  • 08 Dec 2022 Phase-I/II clinical trials in Liver cancer (Inoperable/Unresectable, Second-line therapy or greater, Monotherapy) in Italy (IV)
  • 06 Dec 2022 Phase I/II is still ongoing for Liver cancer (Inoperable/unresectable, Second-line therapy or greater) in Italy (IV) (EduraCT-2020-001002-26)
  • 26 Oct 2022 Efficacy, adverse events and pharmacokinetics data from phase I/II MPSA-153-001 trial in Liver cancer presented at 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top